Clinical Trial Update: Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial evaluating Sym004 in combination with nivolumab for EGFR-amplified squamous non-small cell lung cancer has been withdrawn, comparing the comb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Sym004
• nivolumab (nivolumab)

Snippet

Sponsor: Symphogen A/S | Conditions: Squamous Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: WITHDRAWN